Eton Pharmaceuticals (NASDAQ:ETON) Lowered to Strong Sell Rating by Zacks Research

by · The Cerbat Gem

Zacks Research cut shares of Eton Pharmaceuticals (NASDAQ:ETON – Free Report) from a hold rating to a strong sell rating in a research report sent to investors on Thursday,Zacks.com reports.

Other research analysts have also recently issued reports about the stock. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $29.67.

Check Out Our Latest Analysis on ETON

Eton Pharmaceuticals Stock Performance

ETON stock traded up $0.06 during midday trading on Thursday, hitting $16.94. The company’s stock had a trading volume of 207,217 shares, compared to its average volume of 278,710. The stock has a market cap of $454.30 million, a price-to-earnings ratio of -67.76 and a beta of 1.12. The company has a quick ratio of 1.25, a current ratio of 1.63 and a debt-to-equity ratio of 1.19. The stock’s 50-day moving average price is $18.78 and its 200 day moving average price is $17.12. Eton Pharmaceuticals has a 1 year low of $8.43 and a 1 year high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.20). The business had revenue of $22.46 million for the quarter, compared to the consensus estimate of $20.47 million. Eton Pharmaceuticals had a negative return on equity of 11.32% and a negative net margin of 9.50%. On average, equities analysts forecast that Eton Pharmaceuticals will post -0.14 EPS for the current year.

Insider Buying and Selling

In related news, CFO James R. Gruber sold 39,082 shares of Eton Pharmaceuticals stock in a transaction that occurred on Tuesday, August 19th. The shares were sold at an average price of $16.16, for a total value of $631,565.12. Following the completion of the transaction, the chief financial officer directly owned 205,299 shares in the company, valued at approximately $3,317,631.84. The trade was a 15.99% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 16.03% of the company’s stock.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. State of Alaska Department of Revenue purchased a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new stake in shares of Eton Pharmaceuticals during the second quarter valued at about $37,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals in the second quarter worth about $41,000. AlphaQuest LLC bought a new position in Eton Pharmaceuticals in the 1st quarter valued at $53,000. Finally, Police & Firemen s Retirement System of New Jersey purchased a new position in Eton Pharmaceuticals during the second quarter worth about $87,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

(Get Free Report)

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.

Featured Stories